# A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435

> **NCT01209117** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 24 (actual)

## Conditions studied

- Infections, Human Immunodeficiency Virus and Herpesviridae
- Infection, Human Immunodeficiency Virus

## Interventions

- **DRUG:** GSK2248761 WBM Capsule
- **DRUG:** GSK2248761 WBM Tablet Formulation 1
- **DRUG:** GSK2248761 WBM Tablet Formulation 2
- **DRUG:** GSK2248761 WBM Tablet Formulation 3
- **DRUG:** GSK2248761 WBM Tablet

## Key facts

- **NCT ID:** NCT01209117
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01209117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01209117, "A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01209117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*